bion-1301
bion-1301: developed by 1 company · 4 clinical trials tracked.
bion-1301 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could bion-1301 → KDNY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| CHINOOK THERAPEUTICS, INC. (KDNY) IgA nephropathy (IgAN) | Phase 1/Phase 2 |
Clinical Trials (4)
An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.
Primary endpoint: Change in mesangial IgA deposition
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.
Primary endpoint: Number of participants with adverse events.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
Primary endpoint: Change from baseline in eGFR
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Primary endpoint: Double-blind period: Change in proteinuria
Frequently asked questions
Who is developing bion-1301?
bion-1301 is being developed by CHINOOK THERAPEUTICS, INC..
How many clinical trials involve bion-1301?
BioSniper tracks 4 clinical trials involving bion-1301.